Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Will Slew of Patent Bills Lower Drug Prices?

Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.

Legislation Pricing Debate

Medicxi Closes €400m Medicxi III Biotech Fund In 6 Weeks

European life sciences investment firm Medicxi shows institutional investor appetite for life sciences venture capital is still strong as it secures €400m in an over-subscribed offering.

Commercial Financing

US Generics Market Isn't Stabilizing Yet, Sandoz Says

Novartis's Sandoz unit is the first of the big generics players to report second quarter financials, and its outlook for the US market remains pessimistic.

Generic Drugs Biosimilars

Novartis CEO Calms Concerns Over Zolgensma launch

The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.

Launches Sales & Earnings
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register